Skip to product information
1 of 8

Run the RP role under EU GDP: suppliers, returns, recalls, transport and FMD, with documented decisions.

  • PDF guide
  • 24 editable tools
  • Future releases included
Regular price €149,00 EUR
Regular price Sale price €149,00 EUR
Sale Sold out
Taxes included. Digital product – immediate access after payment.
Language of the purchased files

Choose the Italian or English edition. The website language does not change the file language.

Download after payment · No shipping

View full details

Contents & tools

Inside the guide

Explore the programme, examples and included resources before choosing.

Second edition · Rev. 2.0 · regulatory verification 31/10/2026

From supplier to customer: which text governs each step of wholesale distribution, with what legal force, in which jurisdiction, and where the RP's decision is recorded.

An operational guide for the Responsible Person (RP) and those who work with the RP: authorisation and the legal supply chain, GDP 2013/C 343/01 chapter by chapter, supplier and customer qualification, returns, falsified medicines and recalls, transportation and excursions, brokers, safety features (FMD), import and export, the interface with the QP, shortages and GDP inspection, with Italy, the United Kingdom and a comparison with the United States (DSCSA). 25 chapters in six parts, 5 appendices and 24 editable tools in Word and Excel.

245 pages (ENG) · 246 (ITA) · A4 PDF25 chapters in six parts + 5 appendices24 tools: 6 Word + 18 Excel144 source IDs in the registerStatus and nature labelsDigital product: download after payment
One language per purchase, chosen by the variant. The ENG - English variant gives you the PDF guide and the 24 tools in English; the ITA - Italiano variant gives them in Italian. Both editions have the same structure, the same tools and the same RP-TK-01…24 codes. There are no French, German or Spanish files.

What has changed since Rev. 1.0

Rev. 2.0 is a rewritten second edition, not a set of corrections. Rev. 1.0 (August 2025) covered the EU and Italy, with no toolkit and no labels. Since then the DSCSA timeline and the status of the EU pharmaceutical reform have changed; other points, such as the FMD in Italy, Northern Ireland and the requirements for the Italian persona responsabile, were already outdated or inaccurate, and other gaps in that edition were structural. If you own Rev. 1.0, this is what you will find different.

TopicRev. 1.0 (August 2025)Rev. 2.0 (verified 31/10/2026)
ScopeEU and ItalyEU/EEA, Italy, Great Britain and Northern Ireland, US comparison and regulatory horizon
Structure16 chapters and one operational appendix25 chapters in six parts, Appendices A–E
Toolkitnone24 tools RP-TK-01…24, 18 Excel and 6 Word, one file per tool
Labels and sourcesno labels; sources without version or access datea status label and a nature label on every regulatory statement; 144 source IDs with the point cited, verified as of 31/10/2026 (Appendix D)
Nature of the GDPleft unclear; a revision described as "likely"double anchoring: GDP paragraph and Article 80(g) of Directive 2001/83/EC; no revision in progress
The Italian persona responsabilecontradictory requirements; AIFA for the authorisation and the certificatefour degrees and no statutory minimum experience (Article 101 of Legislative Decree 219/2006); the Region or autonomous Province authorises; supply to pharmacies within twelve working hours
FMD in Italyobligations dated 2019obligations from 09/02/2025 (Legislative Decree 10/2025), stabilisation until 08/02/2027
United KingdomabsentGreat Britain and Northern Ireland, RP and RPi; Regulation (EU) 2023/1182 from 01/01/2025 for medicines intended for Northern Ireland
United Statesthree linesDSCSA, State licensing, 21 CFR 205 and the designated representative: there is no RP in the US
EU pharmaceutical reformdescribed as a revision under way in 2022-2023Council first-reading position of 28/09/2026, treated as [DRAFT] and in conditional wording only; correlation table in Appendix B
Inspections and remote RPfrequencies without a source; conflicting datesCoUP procedures since 01/01/2024; EMA document of 22/05/2024: remote RP activities only if the authority of the site accepts them
RP–QP interface"release for distribution"QP certification, receipt and transfer to saleable stock as distinct acts
Cases and decisions"real" cases without a source; values without a sourcea single fictitious company with five integrated cases; 85 decisions with a D code, with no preloaded values

Rev. 1.0 should no longer be used as an operational reference. The front matter of the guide gives the full comparison, with the chapter that deals with each change.

The problems it tackles

The misconceptions the guide takes apart, each traced to a text with its source ID, its status and its legal force in the jurisdiction where it applies.

"The RP must be a pharmacist." In the EU the GDP state that a degree in pharmacy is "desirable": a wish, while the qualification itself is set by national law. In Italy Article 101 of Legislative Decree 219/2006 admits four degrees (pharmacy, chemistry, pharmaceutical chemistry and technology, industrial chemistry) and sets no minimum experience (Chapters 3 and 21).

"The GDP set 15–25 °C." The GDP do not define "ambient" temperature: 15–25 °C is a WHO recommendation for a storage statement. The RP derives the limits of an area from the labels of the products stored in it (Chapter 7).

"The MKT rescues the excursion." Mean kinetic temperature summarises thermal exposure but does not justify an excursion: the RP's decision is written with duration, maximum temperature, label conditions and the marketing authorisation holder's stability data (Chapter 13; RP-TK-10).

"The FMD has applied in Italy since 2019." Delegated Regulation (EU) 2016/161 applies from 09/02/2019, but in Italy the safety-feature obligations apply from 09/02/2025 (Legislative Decree 10/2025), with a stabilisation period until 08/02/2027 in which the pharmaceutical stamp and the unique identifier may coexist (Chapters 15 and 21).

"The FMD applies in Northern Ireland." Since 01/01/2025 medicines intended for the Northern Ireland market do not bear the EU safety features (Regulation (EU) 2023/1182), and the FMD does not apply anywhere in the United Kingdom (Chapters 15 and 22).

"The US has an RP." There is no Responsible Person in the United States: wholesale distribution requires a State licence and compliance with the DSCSA; State laws such as Florida's require a designated representative, who is not an RP (Chapter 23).

"The EU reform is in force." As of 31/10/2026 there is the Council first-reading position of 28/09/2026: the acts are not adopted, not published in the Official Journal and have no application dates. The guide discusses them only in the conditional, for readiness (Chapter 25; RP-TK-22).

The guide
25 chapters in six parts, each built on a question the RP has to answer, and 5 appendices. Every regulatory statement carries a status label and a nature label and a source ID with the point cited; Appendix D resolves the 144 IDs. Chapters 1–23 close with a guided or integrated case, inspector questions with expected evidence and red flags, and an operational checklist.
The toolkit
24 tools: 6 Word templates and 18 Excel workbooks, one file per tool, with the same RP-TK code as the book. The Excel workbooks have README, PARAMETERS, LISTS, TEMPLATE, EXAMPLE, TEST and SOURCES sheets; the 85 decisions the sources leave to the company are never preloaded: in the PARAMETERS sheets an empty criterion leads to "Assessment required" until you enter it. No tool decides, qualifies or releases: it records and compares.
One case, from start to finish
Selvarda Pharma Distribution S.p.A., a fictitious company, has a warehouse in Italy, a subsidiary in Ireland and contracted premises at a 3PL; three products, six batches and 23 counterparties run through the chapters and the EXAMPLE sheets. Five integrated cases: a suspicious offer (Ch. 9), a recall (Ch. 10), an excursion with a leg without data (Ch. 13), a batch available in the WMS before certification (Ch. 18), a GDP inspection (Ch. 20). Its figures are declared fictitious and are not recommendations.
Regulatory status verified as of 31/10/2026

Every present-tense verb in the guide describes the status of the sources as of 31/10/2026. The points that most often change how a source is read:

  • GDP 2013/C 343/01: applicable since 24/11/2013; Article 80(g) of Directive 2001/83/EC requires the WDA holder to comply with them; no revision is in progress.
  • EU pharmaceutical reform: Council first-reading position of 28/09/2026; the acts await the European Parliament's second reading and are not adopted, not published in the Official Journal and have no application dates. The Critical Medicines Act also remains a proposal.
  • Italy: safety-feature obligations from 09/02/2025 (Legislative Decree 10/2025), with stabilisation until 08/02/2027; the AIFA list of critical shortages is in development (consultation closed on 30/10/2026).
  • United Kingdom: in Great Britain the EU GDP apply as they stood on 31/12/2020, and wholesalers importing from approved countries name an RPi; in Northern Ireland the current Commission GDP apply; since 01/01/2025 the FMD has not applied anywhere in the United Kingdom.
  • United States: DSCSA package-level electronic tracing since 27/11/2023; the exemption for wholesale distributors expired on 27/08/2025, the one for small business dispensers runs until 27/11/2027; 21 CFR 205 sets the minimum standards for State licensing.

Updates included. The guide lists the events that call for a fresh verification of status: the European Parliament plenary indicated for 23/11/2026 and publication of the reform in the Official Journal, the final texts of the EudraLex drafts, new Commission Q&A on safety features, the end of the FMD stabilisation period in Italy, the AIFA list of critical shortages. When the texts change you receive the revised guide and toolkit at no extra cost.

The 24 tools, in six groups

Exact titles of the English edition, grouped by area of the RP's work. No operational value that a source does not fix is preloaded: where one is needed, the field stays <to be defined>, with the D code, who decides, on what basis and where it is recorded.

Applicability, sources and the RP's role · Chapters 1–4
EXCEL
RP-TK-01 · Applicability, Source Status and Horizon Scanning Register
Dated status of every source with labels and jurisdiction, next verification, and the Chapter 25 events that require procedures and tools to be reopened.
WORD
RP-TK-02 · RP Charter and Letter of Appointment, Delegations and Deputy
Basis and scope of the role, authority and resources, the twelve responsibilities of GDP 2.2, delegation register and deputy.
EXCEL
RP-TK-03 · RP Qualification, Experience and Continuing Training File
Requirements by regime (EU, Italy, GB, NI), with law and guidance on separate rows; it checks documentary consistency and does not replace recognition by the authority.
EXCEL
RP-TK-04 · Applicability Checker: WDA, MIA, Broker, Active Substances, Import/Export, GB/NI/EU, RPi
For each activity or flow it shows the title required (WDA, MIA, broker or active-substance registration), the out-of-scope cases and when an RPi is needed.
Quality system, personnel, documents and management review · Chapters 5, 6, 8 and 12
WORD
RP-TK-21 · SOP "GDP Quality System and RP Responsibilities"
Master procedure with fixed sections: responsibilities, risk management, documentation and retention, personnel, operations, recalls; approved and signed by the RP.
EXCEL
RP-TK-08 · GDP Personnel Training and Competence Matrix
Role × module, training record and documented assessment of its effectiveness within the deadline set by the company.
EXCEL
RP-TK-14 · GDP Deviation, Change Control and CAPA Register
Deviations, CAPA with effectiveness checks, eight-step change control and findings: a deviation that requires a CAPA cannot be closed without one.
EXCEL
RP-TK-16 · Diagnostic KPI Dashboard, Management Review Inputs and 30/60/90 Plan
Indicators with their own numerator, denominator and distortion risk, thresholds left to the company, GDP 1.4 inputs and a plan in three windows: 30, 60 and 90 days.
WORD
RP-TK-24 · GDP Management Review Minutes and RP Reports to Management
Minutes with the GDP 1.4 inputs, decisions, resources and actions, plus the RP's written report when a risk or a refused resource calls for one.
Supply chain, counterparties, premises and agreements · Chapters 1, 7, 9 and 11
EXCEL
RP-TK-06 · Supply Chain Map: Sites, Authorisations, EudraGMDP, Due Dates
Chain nodes with verified title, inspection, certificate and the five-year reference from the inspection; it never declares a GDP certificate "expired".
EXCEL
RP-TK-07 · Supplier and Customer Qualification: Bona Fides, Due Diligence, Register and Review
Verified title, due diligence, review, broker registration and an offer register with the EMA Q&A indicators; the counterparty's status remains a choice made by the RP.
EXCEL
RP-TK-09 · Premises, Equipment, Mapping, Calibration and Computerised Systems Register
Areas with limits taken from the labels, calibration and traceability, mapping after a change, logger checks, systems and restore tests.
WORD
RP-TK-05 · GDP Schedule to the Technical Agreement for Outsourced Activities
Parties, authorisations and an activity table with records, deviations, changes and audits; subcontracting only after assessment, written approval by the RP and audit.
Transportation, excursions and receipt · Chapters 7, 13 and 18
EXCEL
RP-TK-17 · Transport Route Assessment and Carrier Qualification
Route profiles, time out of range per leg, carrier audits and subcontracting: a leg without data leads to "Assessment required".
WORD
RP-TK-10 · RP Decision Record: Excursions and Final Disposition of Product
A signed record per event: available data, the marketing authorisation holder's assessment, criteria applied and the RP's decision, with no MKT and no excursion budget.
EXCEL
RP-TK-18 · Receipt and Transfer to Saleable Stock Register (QP–RP Interface, Control Report)
Quarantine, proof of release, approval and transfer to saleable stock in sequence, batch by batch.
Complaints, returns, falsified medicines, recalls and FMD · Chapters 10 and 15
EXCEL
RP-TK-11 · Complaints, Returns and Suspected Falsified Medicinal Products Register
Complaints; returns with the GDP 6.3 conditions and calculated working days; suspected products with segregation and notifications. The RP's decision is a recorded choice.
EXCEL
RP-TK-12 · Recall Plan, Mock Recall and Reconciliation
Contacts, message and reconciliation by customer (shipped, returned, destroyed, blocked, in transit, dispensed), with the annual effectiveness check the GDP require.
EXCEL
RP-TK-13 · FMD Checklist and Alert Management for the Distributor
Decision tree for Articles 20–23 of Delegated Regulation (EU) 2016/161 by flow and an alert register with triage and segregation; GB and NI "not applicable" since 01/01/2025.
Import/export, shortages, inspection and reform · Chapters 16, 19, 20 and 25
EXCEL
RP-TK-19 · Import/Export, Third Countries, Active Substances and Written Confirmation Register
For each movement the title required (MIA for the EU market, WDA or MIA for export), the restriction lists consulted and the written confirmation for active substances.
EXCEL
RP-TK-20 · Shortages, Export Restrictions and Authority Notifications Register
Shortage signals, urgent requests from Italian pharmacies against the statutory limit of twelve working hours, allocation and replies to the authorities.
EXCEL
RP-TK-15 · GDP Self-Inspection Programme and Chapter-by-Chapter Checklist
A programme covering the ten GDP chapters within the timeframe chosen by the company, a checklist by paragraph with expected evidence, findings and mock inspections.
WORD
RP-TK-23 · GDP Inspection Readiness Dossier and Question Bank
Basis of the inspection, host team, dossier index, logistics and the bank of 48 questions from Chapter 20 with expected evidence.
EXCEL
RP-TK-22 · EU Pharmaceutical Reform Readiness Check [DRAFT]
Today's law and the Council text compared in six areas, with reasoned impact and relative phases: no application dates, and the file is marked [DRAFT].

In the ITA - Italiano variant the same 24 tools carry the titles of the Italian edition and the same RP-TK-01…24 codes. Each Excel workbook contains an EXAMPLE sheet filled in with the Selvarda case; each Word file has an EXAMPLE annex, with the banner "FICTITIOUS EXAMPLE — DO NOT USE OPERATIONALLY".

Use it tomorrow morning

The situationWhat you use
Appointing an RP or designating a deputyChapter 3 + RP-TK-02 and RP-TK-03: requirements by jurisdiction, letter of appointment, the twelve responsibilities of GDP 2.2, recorded delegations.
A suspicious offer of a medicine in short supplyChapter 9 (Case C) + RP-TK-07: bona fides, EMA Q&A indicators, refusal and notification.
A return to be put back into saleable stockChapter 10 + RP-TK-11 and RP-TK-10: GDP 6.3 conditions, a limit set by the distributor rather than "10 days by law", the RP's decision on record.
A recall whose reconciliation does not balanceChapter 10 (Case B) + RP-TK-12: shipped, returned, destroyed, blocked, in transit and dispensed, customer by customer, down to zero discrepancy.
A transport excursion with a leg without dataChapter 13 (Case A) + RP-TK-17 and RP-TK-10: complete profile, the marketing authorisation holder's assessment, no decision based on MKT.
An FMD alert at goods receiptChapter 15 + RP-TK-13 and RP-TK-11: verification, decommissioning, segregation and notification as distinct acts.
A batch "available" in the WMS before proof of releaseChapter 18 (Case E) + RP-TK-18: quarantine, proof of release, approved transfer to saleable stock.
Shipments to Great Britain or Northern IrelandChapter 22 + RP-TK-04 and RP-TK-19: title required, RPi, "UK Only" packs, FMD not applicable.
A routine GDP inspection at the warehouseChapter 20 (Case D) + RP-TK-23 and RP-TK-15: dossier, bank of 48 questions, deficiencies, response and CAPA.
Preparing the organisation for the EU reformChapter 25 and Appendix B + RP-TK-22: readiness on the Council text, with no application dates and without treating it as an obligation.
What the guide does not do

It does not invent numbers. No universal value for "ambient" temperature, acceptable excursion duration, audit or self-inspection frequency, returns limit, response time or KPI threshold. The only two numerical frequencies in the GDP (recall and monitoring during transportation) appear with their source; every other value stays <to be defined> with its D code.

It does not treat drafts as law. The EU pharmaceutical reform, the Critical Medicines Act and the drafts of EudraLex Chapter 1, Chapter 4, Annex 11 and Annex 22 carry the [DRAFT] label: they serve readiness, not a current decision.

It does not decide for the RP. No tool decides, qualifies or releases: states such as "QUALIFIED" or "RETURNED TO SALEABLE STOCK" are choices recorded by the RP or by an authorised person.

It is not legal advice. It describes texts, status and legal force of the sources; quotations are short and verbatim, provisions are paraphrased. For a specific case the text in force and the competent authority prevail.

Contents: six parts, 25 chapters

Chapter titles of the English edition. Chapters 1–23 close with inspector questions, an operational checklist and the toolkit tools with the chapter's sources.

Part I — The RP and GDP in EU law
  1. 1. Wholesale distribution: activities, authorisation (WDA) and the legal supply chain of medicines
  2. 2. The EU legal basis and the status of sources
  3. 3. The Responsible Person: requirements, appointment, availability, delegation and accountability
  4. 4. Applicability and jurisdictions: who needs which authorisation
Part II — The GDP quality system
  1. 5. Quality system, risk management and management review (GDP Chapter 1)
  2. 6. Personnel, training and hygiene (GDP Chapter 2)
  3. 7. Premises, equipment, qualification and computerised systems (GDP Chapter 3)
  4. 8. Documentation and records (GDP Chapter 4)
  5. 9. Operations: supplier and customer qualification, receipt, storage, supply and destruction (GDP Chapter 5)
  6. 10. Complaints, returns, suspected falsified medicinal products and recalls (GDP Chapter 6)
Part III — Outsourcing, transportation and complex routes
  1. 11. Outsourced activities and technical agreements (GDP Chapter 7)
  2. 12. Self-inspections and performance indicators (GDP Chapter 8 and 1.4)
  3. 13. Transportation: routes, carriers, excursions, vehicles and containers (GDP Chapter 9)
  4. 14. Brokers and intermediaries (GDP Chapter 10 and Article 85b)
  5. 15. Safety features and the FMD for the distributor
  6. 16. Import, export, third countries, free zones and active substances
  7. 17. Special products and flows: narcotics, medicinal gases, radiopharmaceuticals, blood products, dangerous goods and IMPs
Part IV — Interfaces and incidents
  1. 18. The RP–QP interface: receipt, control report and transfer to saleable stock
  2. 19. Shortages, public service obligation (Article 81), export bans and market signals
  3. 20. GDP inspection: procedure, GDP certificate and statement of non-compliance, deficiencies, response and CAPA
Part V — National overlays and comparisons
  1. 21. Italy: Legislative Decree 219/2006, Title VII, and the persona responsabile
  2. 22. United Kingdom: HMR 2012 Part 3, RP and RPi, Great Britain and Northern Ireland
  3. 23. United States: DSCSA, State licensing, 21 CFR 205 and the designated representative (no RP)
  4. 24. Synoptic comparison EU – Italy – United Kingdom – US
Part VI — Regulatory horizon
  1. 25. The EU pharmaceutical reform, the Critical Medicines Act, the DSCSA timeline and other ongoing revisions

Appendices A–E. A Full map of the GDP Guidelines 2013/C 343/01 · B Correlation table Directive 2001/83/EC ↔ Council text of the reform · C ITA–ENG glossary · D Source register (144 IDs) · E Toolkit index and decisions to be recorded.

What the package contains

After payment you download the guide and the toolkit in the language of the variant you chose.

  • The complete PDF guide. 245 A4 pages in the English edition, 246 in the Italian one; clickable contents and bookmarks.
  • 18 Excel workbooks (.xlsx). README, PARAMETERS, LISTS, TEMPLATE, EXAMPLE, TEST and SOURCES sheets; calculated cells protected without a password, against accidental errors; no macros, no external links.
  • 6 Word templates (.docx). Document control with empty fields, tool-specific instructions, stable numbered sections, revision history and an EXAMPLE annex.
  • One file per tool, with an index. File names and RP-TK codes as in Appendix E; the PDF toolkit index lists each tool with its format and related chapters.

Read the preview before you buy

The free preview is made of real pages of the guide (full contents, label legend, chapter pages and tool screens): 16 pages in the English edition, 16 in the Italian one.

Specifications

FormatA4 PDF with clickable contents and bookmarks; tools in .docx and .xlsx
Pages and chapters245 pages (ENG edition) · 246 pages (ITA edition) · 25 chapters in six parts + 5 appendices (A–E)
Toolkit24 editable tools: 6 Word + 18 Excel, codes RP-TK-01…24, one file per tool
File languagesOne language per purchase: ENG - English or ITA - Italiano. There are no French, German or Spanish files.
Edition and revisionSecond edition · November 2026 · Rev. 2.0 · tools rev. 1.0; supersedes Rev. 1.0 (August 2025)
Regulatory verification31/10/2026 (status of every source on that date)
JurisdictionsEU/EEA · Italy · United Kingdom (Great Britain and Northern Ireland) · US comparison (DSCSA)
Sources and labels144 source IDs in the Appendix D register · status and nature labels
Free preview16 pages (ENG edition) · 16 pages (ITA edition)
UpdatesWhen the texts change you receive the revised guide and toolkit at no extra cost.
DeliveryDigital product: download after payment. Nothing is shipped: the 3D image of the volume is a graphic representation; there is no printed book.
Software requirementsA PDF reader; Microsoft Word and Excel (formulas compatible with Excel 2016 and later) or compatible programs: the Excel workbooks were recalculated with LibreOffice during testing. No macros, no external links.
LicenceIndividual use and internal use within the purchasing company: a personal, non-exclusive, non-transferable licence under the site's Legal Notice; printing for internal use only; sharing the files with third parties is not permitted.
Limits of use
  • The Excel workbooks are calculation templates with test sheets, not GMP-validated software: before GxP use the company verifies them in its own system, repeating the cases in the TEST sheet.
  • Selvarda Pharma Distribution S.p.A. is a fictitious company: its sites, authorisations, people, products, batches, events and figures are invented and are neither criteria nor data of a real company.
  • No tool decides, qualifies or releases: the RP's decisions are choices recorded by whoever holds the authority.
  • The guide does not replace the official texts it cites and is not personalised legal, regulatory or quality advice.
  • The inspector questions are written for teaching purposes, anchored to the texts cited; they do not reproduce questions from an authority. No outcome of an audit or inspection is guaranteed.

Who it is for. RPs in post or designated in the EU/EEA, the Italian persona responsabile (Article 101 of Legislative Decree 219/2006), RPs and RPis in the United Kingdom, deputies and people with documented delegations, quality managers of wholesalers, third-party logistics providers (3PLs) and depositaries, brokers, QA of MIA holders distributing their own products, import and supply chain managers, quality units of US wholesale distributors with EU counterparties, auditors and consultants. It assumes the reader knows a pharmaceutical warehouse and its own WMS.

Who it is not for. It does not cover veterinary medicinal products (Implementing Regulation (EU) 2021/1248), medical devices, national provisions of Member States other than Italy or clinical trial rules. Technical qualification of the cold chain, batch certification, data integrity governance, computerised system validation, the manufacturer's pharmaceutical quality system, the general method for investigating deviations and managing CAPA, pharmacovigilance, marketing authorisations and variations stay in the sister guides: here only the aspects the RP needs appear.

Frequently asked questions

In which language do I receive the files?

In the language of the variant you choose: ENG - English or ITA - Italiano. Each purchase includes the guide and the toolkit in one language only. There are no French, German or Spanish files.

Is it a printed book?

No. It is a digital product: after payment you download the PDF and the 24 tools in .docx and .xlsx. Nothing is shipped; the 3D image is only a representation of the volume.

I own Rev. 1.0: what changes?

Rev. 2.0 is a rewritten second edition: 25 chapters instead of 16, 24 tools where there was no toolkit, status and nature labels, the United Kingdom and the United States alongside the EU and Italy, the FMD in Italy from 09/02/2025, and the EU reform as it stood on 28/09/2026. The table on this page summarises the differences; Rev. 1.0 should no longer be used as an operational reference.

What happens when the reference texts change?

The guide lists the events that call for a fresh verification, starting with the European Parliament plenary on the reform and its publication in the Official Journal. When the texts change you receive the revised guide and toolkit at no extra cost. The revision on sale is shown on this page, with the date of the regulatory verification.

Can I use the tools in my company?

Yes: the licence covers individual use and internal use within the purchasing company; you adapt the templates to your procedures and enter your own criteria in the PARAMETERS sheets. Sharing the files with third parties, including external suppliers and consultants, is not permitted; printing is allowed for internal use only.

Do the tools tell me whether a return can be restocked or a supplier is qualified?

No. The only outcomes are "Comparison with the entered criteria" or "Assessment required", with the reason; states such as "QUALIFIED" or "RETURNED TO SALEABLE STOCK" are recorded by the RP or by an authorised person.

Are the Excel workbooks validated?

They are not GMP-validated software. Each has a TEST sheet with the test cases, expected result and calculated result, and a SOURCES sheet with the IDs used: the company verifies them in its own system before GxP use.

Do you have a flow, an authorisation or an RP decision to sort out?
Describe the activity, the flow, the jurisdictions involved and the point where you are stuck. GuideGxP will review the request and, where appropriate, may put you in touch with a specialist suited to your technical needs and your geographical area.
Describe your situation →
No purchase required. Each request is reviewed before any referral to a specialist.

GuideGxP guides do not replace official legislation or the guidance they cite (European Commission, EMA, PIC/S, WHO, MHRA, AIFA, FDA): they are operational support tools, they are not legal advice, and users remain responsible for correctly applying the rules in force in their own company context. Decisions on returns, excursions and transfer to saleable stock remain acts of the RP. The EU pharmaceutical reform, the Critical Medicines Act and the EudraLex drafts are not adopted and are marked as such. Regulatory status verified as of 31/10/2026. Selvarda Pharma Distribution S.p.A. is a fictitious company. Digital product: nothing is shipped.

DECLARED REGULATORY BASIS

Built on the most up-to-date official sources.

Every guide is built from the official sources current at the editorial verification date stated in the document. The editions, revisions and cut-off dates used are declared and checked again for every new release; requirements are kept distinct from GuideGxP operational interpretation.

Main references for this guide EU GDP Guidelines (2013/C 343/01) · EU GMP · MHRA GDP guidance
  • Editions and revisions stated in the document
  • Explicit editorial verification date
  • Requirements separated from practical recommendations

GuideGxP is an independent publisher and is not affiliated with, approved by or sponsored by the authorities and organisations cited.

INCLUDED WITH YOUR PURCHASE

Every new release is delivered automatically by email.

Buy once: whenever we publish a new release of the guide you purchased, it is sent automatically to the email address used for the order, together with the download link. No request, new registration or additional payment is required.

  • Every future release included for life
  • Automatic delivery to the order email
  • Average review cycle: 6 months

Timing may vary with regulatory and technical developments. No action is required after purchase; simply use a valid email address at checkout.

A PRACTICAL PERSPECTIVE

Experiences with our guides and toolkits.

Perspectives on using GuideGxP guides and toolkits.

The editable files are the most useful part. I read the explanation in the guide, then work on the documents without starting from scratch.

Raphaela M.QA Specialist
Guides and toolkits

The templates need adapting to your site. But having a well-considered structure is very different from starting with a blank page.

Ramón María G.Validation Manager
Guides and toolkits

I wanted practical support, not another collection of definitions. The examples helped me connect the reading to the work we do in the laboratory.

Philippine M.QC Laboratory Manager
Guides and toolkits

I read the preview before buying. It helped me understand the guide’s approach and whether it covered what I was looking for.

Haraldur P.Quality Specialist
Guides and toolkits

I choose the templates the project needs and adapt them. For me, the benefit is having a consistent starting point.

Kael B.Validation Engineer
Guides and toolkits

I keep it as a reference while we review procedures. I can return to the topic I need without reading everything again from the beginning.

Isabella L.Quality Assurance Manager
Guides and toolkits

Explanation and tools in the same package: first I understand why an activity matters, then consider how to approach it in our context.

Napoléon L.Production Manager
Guides and toolkits

Some topics need careful reading, but I like the practical approach. It gave me useful ideas for reviewing how we organise our documentation.

Elwin L.Quality Systems Manager
Guides and toolkits

I wanted to understand how the topic translates into daily activities. I found a useful basis for discussing with QA what needed clarifying in our instructions.

Anne-Sophie M.Production Department Head
Guides and toolkits

I chose the guide after checking the included content. I like that the material is designed to be used and adapted, as well as read.

Andrea M.Compliance Specialist
Guides and toolkits

It helped align terminology across different functions. A shared outline makes it easier to discuss requirements, responsibilities and the documents to prepare.

Are Ø.Project Manager (Tech Transfer)
Guides and toolkits

I mainly use it to organise a topic before an internal discussion. The value is having explanations, references and tools within the same learning path.

Nik U.GMP Consultant
Guides and toolkits
Use the arrows, drag the cards or choose “Read all”.

Delivery & FAQs

Before you buy

A question before you buy?

Contact us
How do I receive my files?

After payment confirmation, download instructions are sent to the order email address. This is a digital product, with no physical shipping.

Is the guide in the website language?

The available editions are Italian and English. Select the file language before adding the product to your cart.

Are updates included?

Future releases of your purchased guide are included and sent to the order email address. Timing depends on regulatory and technical developments.

Can I adapt the templates to my quality system?

Where Word and Excel files are included, you can adapt them to your context. The contents require professional judgement and do not replace official regulations.